MarketBeat
16 Nov 2026, 08:12 UTC · 17h ago
Cytokinetics' MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
Impact · against what's priced in
CYTK is seeing strong early commercial traction for MYQORZO with significant new-to-brand share and improving commercial coverage. The roadmap toward cash-flow positivity within 30 months and upcoming regulatory submissions for nHCM provide a concrete catalyst for valuation expansion.
- CYTK+0.70
No priced-in read yet





